Table 3.
| Study | Demographics | Clinical subgroups | Baseline GFR | Intervention |
|---|---|---|---|---|
| Pfeffer et al59 Heart disease subset of TREAT multicenter, international 29 months |
n: 1287 versus 1355 (2636/4044 enrolled had CvD) male: 46, mean age: 70 White: 69, Black: 19, Hispanic: 9.3 |
CVD: 67.9 CHF: 50.2 PAD: 31.8 RAAS blockers: 77.7 |
GFR: 34 | Darbepoetin alpha titrated to high (13.0 g/dL) versus low (9.0 g/dL) Hgb target |
| Singh et al58 CHF subset of CHOIR 36 months |
n: 192 versus 183 mean age (Hgb 13.5 group versus Hgb 11.3 group): 70.2 versus 69.5 male: 46.4 versus 56.3 Black: 29.3 versus 27.3 Hispanic: 9.4 versus 12.0 |
CHF | GFR: 26.9 versus 26.0 | Epoetin alpha titrated to high (13.5 g/dL) versus low (11.3 g/dL) Hgb target |
| Drüeke et al57 Open-label, randomized CREATE |
n: 600 Group 1: target Hgb of 13–15 and group 2: target Hgb of 10.5–11.5 Mean age: 59.3 versus 58.8 years Male 57 versus female 51 |
CHF: 33% versus 31% ACEI: 51% versus 47% ARB: 19% versus 22% |
GFR: 24.9 versus 24.4 mL/min | Epoetin beta 2000 units SQ weekly to achieve target Hgb 13–15 in group 1 versus 10.5–11.5 in group 2 |
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CHF, congestive heart failure; CVD, cardiovascular disease; GFR, glomerular filtration rate; Hgb, hemoglobin; NIH, National Institutes of Health; TSAT, transferrin saturation; CREATE, Cardiovascular Reduction Early Anemia Treatment Epoetin beta; CHOIR, Correction of Hemoglobin Outcomes in Renal Insufficiency; RAAS, renin-angiotensin-aldosterone system; TREAT, Trial to Reduce Cardiovascular Events with Aranesp® Therapy.